Prostate Cancer International is
for 2011 by Great NonProfits
News and information provided on this site should not be used for diagnosing or treating any health problem or disease.
The "New" Prostate Cancer InfoLink is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.
A new article by Antonarakis and Armstrong in full text on the Medscape web site reviews available information on a wide range of currently investigational agents for the treatment of metastatic, castration-resistant prostate cancer (mCRPC), including
Filed under: Drugs in development, Management, Treatment | Tagged: advanced, castration-resistant, investigational, mCRPC, metastatic | 3 Comments »
In May 2010 we reported that a product called eribulin mesylate had been tested (in the USA) in a Phase II clinical trial for its activity in metastatic, castration-resistant prostate cancer (mCRPC) — and that the results were not particularly promising.
Filed under: Drugs in development, Management, Treatment | Tagged: castration-resistant, eribulin, mCRPC, metastatic | 3 Comments »
We apparently managed to overlook a series of three review and commentary articles published in Oncology in May this year that dealt with the evolving options that have already — or will soon — come available for the treatment of castration-resistant prostate cancer (CRPC).
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, CRPC, hormone-resistant, mCRPC, metastatic | 2 Comments »
According to a retrospective analysis of data from a randomized, double-blind, Phase III clinical trial, abiraterone acetate (Zytiga™) can significantly lower levels of fatigue in men with metastatic, castration-resistant prostate cancer (as well extending survival).
Filed under: Living with Prostate Cancer, Treatment | Tagged: abiraterone, castration-resistant, fatigue, metastatic | 2 Comments »
Oncothyreon, Inc. has announced initiation of a Phase II clinical trial of the company’s investigational agent PX-866 in the treatment of men with chemotherapy-naïve, recurrent or metastatic, castration-resistant prostate cancer (CRPC).
Filed under: Drugs in development, Management | Tagged: castration-resistant, inhibitor, kinase, metastatic, Oncothyreon, PX-866 | Leave a Comment »
Exelexis has issued a media release stating that “the pre-specified number of progression-free survival (PFS) events required for un-blinding of the data for the ongoing Phase III pivotal trial of cabozantinib in patients with medullary thyroid cancer (MTC), known as the EXAM trial, has been reached.”
Filed under: Drugs in development, Management, Treatment | Tagged: cabozantinib, castration-resistant, metastatic | 5 Comments »
According to a media release issued by Bayer HealthCare, the U. S. Food & Drug Administration (FDA) has given the green light to “fast track” review of the company’s new drug application (NDA) for Alpharadin™ (radium-223 chloride) as a treatment for men with metastatic, castration-resistant prostate cancer (mCRPC).
Filed under: Drugs in development, Management, Treatment | Tagged: Alpharadin, castration-resistant, mCRPC, metastatic, radium-223 | 3 Comments »
We have reported on a number of attempts to use tyrosine kinase inhibitors (TKIs) — alone or in combination with chemotherapy — in the treatment of men with castration-resistant prostate cancer (CRPC). Limited activity or efficacy has been reported to date.
Filed under: Drugs in development, Management, Treatment | Tagged: bicalutamide, castration-resistant, CRPC, metastatic, sorefanib, TKI, tyrosine kinase inhibitor | Leave a Comment »
The levels of circulating tumor cells (CTCs) — as evaluated using Cellsearch technology — is becoming accepted as a prognostic marker for disease progression among men with metastatic castration-resistant prostate cancer (mCRPC), and may even be accepted soon as a surrogate marker for prostate cancer-specific mortality in clinical trials of new agents.
Filed under: Living with Prostate Cancer, Management | Tagged: circulating tumor cells, CTC, hormone, hormone-sensitive, metastatic, therapy | 2 Comments »
The investigational radioisotope radium-233 chloride (Alpharadin) has shown a small but clinically significant overall survival benefit in the treatment of men with symptomatic, metastatic, castration-resistant prostate cancer (mCRPC).
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: Alpharadin, castration-resistant, metastatic, radium-233 chloride, survival | 3 Comments »
Preliminary data from a Phase II clinical trial have suggested that the antifungal drug itraconazole, when used at high dose levels, may have clinical benefit in the treatment of metastatic, castration-resistant prostate cancer (mCRPC).
Filed under: Drugs in development, Management, Treatment | Tagged: castration-resistant, itraconazole, mCRPC, metastatic | 2 Comments »
According to a media release issued by Centocor Ortho Biotech late yesterday, the final results of the Phase III clinical trial of abiraterone acetate + prednisone vs. prednisone alone in men with metastatic, castration-resistant prostate cancer (mCRPC) have been published in today’s issue of the New England Journal of Medicine.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: abiraterone, castration-resistant, mCRPC, metastatic | Leave a Comment »
The final report of the result of the ASCENT-2 trial has been published on line in the Journal of Clinical Oncology. The data from this study have been widely reported in the past.
Filed under: Drugs in development, Management, Treatment | Tagged: ASCENT, calcitriol, castration-resistant, DN-101, docetaxel, mCRPC, metastatic | Leave a Comment »
About a decade ago, Abbott Laboratories started to investigate the potential of a selective endothelin receptor antagonist called atrasentan or Xinlay™ for the treatment of advanced forms of prostate cancer.
Filed under: Drugs in development, Management, Treatment | Tagged: atrasentan, castration-resistant, mCRPC, metastatic | Leave a Comment »
TRC105 is a novel angiogenesis inhibitor being developed by TRACON Pharmaceuticals that is expected to have activity against a wide variety of solid cancers, including advanced forms of prostate cancer.
Filed under: Drugs in development | Tagged: castration-resistant, mCRPC, metastatic, TRACON Pharmaceuticals, TRC105 | Leave a Comment »
Blog at WordPress.com. Theme: Digg 3 Column by WP Designer.
Search for new and
ongoing trials on the
CTAG PCa web site